

## Point-by point response to the Reviewers' comments

### Reviewer 1.

- *This work represents an excellent review paper on currently available HCC surveillance tools in patients with chronic liver disease. The authors mainly direct attention at the surveillance tools in patients with chronic HBV and HCV infection. I would like to ask the authors to comment the position of HCC surveillance tools in patients with non-alcoholic fatty liver disease (NAFLD), especially given the significant risk of HCC in patients without liver cirrhosis. The title, abstract, manuscript organization and presentation, discussion, tables and references are appropriate, language clear and understandable.*

Response: Thank you very much for your kind words of appreciation of our paper.

Concerning the comments:

1. We have added a comment regarding the position of HCC surveillance tools in patients with non-cirrhotic NAFLD to the first paragraph of conclusion part as follows;

**-Considering the significant rise in NAFLD-related HCC cases globally, the ability to stratify the risk of HCC is becoming another urgent need. HCC does also occur in patients with non-cirrhotic NAFLD but surveillance is not recommended to this group as incidence rates are lower than 1% a year<sup>[93]</sup>.**

**The HCC risk stratification tools in patients with NAFLD is not discussed here, as the aim of the present article is to focus on HCC surveillance of patients with chronic viral hepatitis.**

Thank you for your kind response and acceptance of our original article.

Best regards.

Coskun Ozer Demirtas, MD

Marmara University, School of Medicine

Department of Gastroenterology and Hepatology

E-mail: [coskun\\_demirtas10@hotmail.com](mailto:coskun_demirtas10@hotmail.com)